Gender specifics of the association between blood fibrinolytic activity and cardiovascular disease or diabetes mellitus in a cohort of Muscovites aged 55 years or older
https://doi.org/10.15829/1728-8800-2012-4-52-58
Abstract
Aim. To investigate potential gender differences in the association between plasma fibrinolytic activity (FLA) and atherosclerotic pathology in elderly people.
Material and methods. This analysis was performed as a part of the prospective population-based cohort study “Stress, Ageing, and Health in Russia”. The study included randomly selected Moscow residents of both genders and age of ≥55 years (n=1863; 889 men and 974 women). Based on the levels of blood FLA (time of spontaneous lysis of euglobin blood fraction, or euglobin lysis time, ELT), all participants were divided into three groups: with normofibrinolysis (ELT 180-260 minutes), hypofibrinolysis (ELT >260 minutes), and hyperfibrinolysis (ELT <180 minutes).
Results. In this cohort of elderly Muscovites, the association between FLA and the presence of cardiovascular disease (CVD) or Type 2 diabetes mellitus (DM-2) differed in men and women. The link between hypofibrinolysis, atherogenic changes in lipid profile, or high fasting levels of insulin and arterial hypertension (AH), myocardial infarction (MI), or DM-2 was present only in men. In women, either reduced or increased FLA was not related to DM-2. Men with hyperfibrinolysis demonstrated lower odds of AH and DM-2, while women with hyperfibrinolysis had lower odds of AH, coronary heart disease, or angina.
Conclusion. In elderly people, high FLA appears to provide protection against atherothrombotic pathology, regardless of gender. Low FLA was associated with higher odds of CVD and DM-2 in men only.
About the Authors
L. A. Ratnikova
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
V. A. Metelskaya
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
N. V. Perova
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
A. D. Deev
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
S. A. Shalnova
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
References
1. Borissoff J, Spronk H, ten Cate H. The hemostasis system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-60.
2. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-38.
3. Borissoff J, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122(8): 821-30.
4. Novelletto BF, Guzzinati S, Avogaro A. Prevalence of metabolic syndrome and its relationship with clinically prevalent cardiovascular disease in the Veneto region, Northeastern Italy. Metab Syndr Relat Disord 2012; 10(1): 56-62.
5. Rudnicka AR, Rumley A, Whincup PH, et al. Sex Differences in the Relationship between inflammatory and haemostatic biomarkers and metabolic syndrome: British 1958 birth cohort. J Thromb Haemost 2011; 9(12): 2337-44.
6. Sclavo M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital Heart J Suppl 2001; 2(2): 125-41.
7. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95(3): 136-47.
8. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of metabolic syndrome among elderly Muscovites. Arch Gerontol Geriatr 2011; doi:10.1016/j. archger.2011.09.005.
9. Ratnikova LA, Metelskaya VA, Shalnova SA, et al. Relationship between activity of fibrinolysis, parameters of lipid spectrum and carbohydrate metabolism. Kardiologiia 2010; 2: 45-50. Russian (Ратникова Л.А., Метельская В.А., Шальнова С.А. Взаимосвязь между активностью фибринолиза, показателями липидного состава крови и углеводного обмена. Кардиология 2010; 2: 45-50.
10. Shkolnikova M, Shalnova S, Shkolnikov V, et al. Biological mechanisms of disease and death in Moscow: rationale and design of the survey on Stress Aging and Health in Russia (SAHR). BMC Public Health 2009; 9: 293-313.
11. Сlinical laboratory analytics. Ed. Menshikov V.V. Moscow. “Labpress” 2000, v. III, p 317. Russian (Клиническая лабораторная аналитика. Под ред. Меньшикова В.В., М «Лабпресс» 2000; т. III: 317 c) .
12. Cesari M, Pahor M, Incalzi R. Plasminogen activator inhibitor-1 (PAI-1): a key factor Linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28(5): e72-91.
13. Juhan-Vague I, Vague P, Alessi MC, et al. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13 (3/2): 331-6.
14. Urano T, Sumiyoshi K, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66 (4): 474-8.
15. Okazaki M, Iwasaki Y, He Jing, et al. Insulin enhancement of cytokineinduced coagulation/Inflammation-related gene transcription in hepatocytes. Endocr J 2008; 55 (6): 967-75.
16. Sakamoto K, Sakamoto T, Ogava H. Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes. Circ J 2008; 72: 844-6.
17. Juhan-Vague I, Alessi M. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemostas 1997; 78: 656-60.
18. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
19. Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007; 27: 1231-7.
20. Schneider DJ, Hayes M, Wadsworth M, et al. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1(PAI-1). J Histochem Cytochem 2004; 52: 1091-2103.
21. Sobel BE. Increased plasminogen activator inhibitor type 1 and vasculopathy. A reconcilable paradox. Circulation 1999; 99: 2496-8.
22. Rocha E, Paramo JA. The relationship between impaired fibrinolysis and coronary heart disease: role for PAI-1. Fibrinolysis 1994; 8: 294-303.
23. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
Review
For citations:
Ratnikova L.A., Metelskaya V.A., Perova N.V., Deev A.D., Shalnova S.A. Gender specifics of the association between blood fibrinolytic activity and cardiovascular disease or diabetes mellitus in a cohort of Muscovites aged 55 years or older. Cardiovascular Therapy and Prevention. 2012;11(4):52-58. (In Russ.) https://doi.org/10.15829/1728-8800-2012-4-52-58
Views:
566
Email this article 
